Watch for the New Combo HIV Meds Symtuza and Biktarvy

June 2018

Symtuza and Biktarvy will be the latest once-daily, single-pill regimens for treating HIV.

Think of these as new complete HIV regimens in one pill...to help improve efficacy due to improved adherence.

Symtuza (sim-TOO-zah, darunavir/cobicistat/emtricitabine/tenofovir alafenamide) will be a first-line option for treatment-naive patients or for those switching from other HIV regimens.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Naloxone Streamline Processes for Providing Naloxone
Anticoagulants Lean Toward Eliquis for the Best Balance of Efficacy and Safety in Atrial Fib
Diabetes Use the New Diabetes Guidelines to Optimize Therapy for Your Type 2 Patients
Diabetes Don't Advise Routine Glucose Monitoring if Results Won't Be Used
Depression Stay Alert for Depression in Teens
Vaccines Recommend Pertussis Vaccination to All Pregnant Women
Practice Use These Tips to Determine Whether Marketing Is Just Hype
Antithrombotics Think of Antiplatelets for Arterial Clots and Anticoagulants for Venous Clots
Asthma Watch for Tiotropium or Biologics for Severe Asthma
HIV & AIDS Watch for the New Combo HIV Meds Symtuza and Biktarvy

Watch for the New Combo HIV Meds Symtuza and Biktarvy

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents